Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem Sells 22,850 Shares

Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 22,850 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $189.14, for a total transaction of $4,321,849.00. Following the sale, the chief executive officer now directly owns 105,770 shares in the company, valued at approximately $20,005,337.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Edwards Lifesciences stock opened at $191.45 on Friday. The company has a fifty day moving average of $182.93. Edwards Lifesciences Corp has a 1 year low of $134.53 and a 1 year high of $197.86. The firm has a market cap of $39.98 billion, a PE ratio of 40.73, a P/E/G ratio of 2.44 and a beta of 0.85. The company has a quick ratio of 2.69, a current ratio of 3.66 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The firm had revenue of $993.00 million for the quarter, compared to analysts’ expectations of $989.87 million. During the same quarter last year, the company earned $1.22 EPS. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. On average, sell-side analysts predict that Edwards Lifesciences Corp will post 5.29 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Clark Capital Management Group Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter valued at $299,000. Diversified Trust Co raised its holdings in shares of Edwards Lifesciences by 16.9% during the 2nd quarter. Diversified Trust Co now owns 2,405 shares of the medical research company’s stock worth $444,000 after acquiring an additional 347 shares during the period. NN Investment Partners Holdings N.V. raised its holdings in shares of Edwards Lifesciences by 32.1% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 34,646 shares of the medical research company’s stock worth $6,400,000 after acquiring an additional 8,424 shares during the period. Evolution Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth $29,000. Finally, Gofen & Glossberg LLC IL raised its holdings in shares of Edwards Lifesciences by 3.8% during the 2nd quarter. Gofen & Glossberg LLC IL now owns 2,427 shares of the medical research company’s stock worth $448,000 after acquiring an additional 88 shares during the period. Institutional investors own 82.00% of the company’s stock.

A number of equities research analysts have recently commented on the stock. Stifel Nicolaus cut shares of Owens Corning from a “buy” rating to a “hold” rating and set a $52.45 price objective on the stock. in a research note on Wednesday, April 24th. Barclays reaffirmed a “sell” rating on shares of Deutsche Bank in a research note on Monday, March 25th. Bank of America assumed coverage on shares of DENTSPLY SIRONA in a research note on Monday, March 18th. They set a “buy” rating and a $57.00 price objective on the stock. Credit Suisse Group raised their price objective on shares of JPMorgan Chase & Co. from $128.00 to $132.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Finally, Canaccord Genuity set a $40.00 price objective on shares of Mallinckrodt and gave the stock a “buy” rating in a research note on Monday, March 18th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Edwards Lifesciences has a consensus rating of “Buy” and an average target price of $188.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: How does a security become overbought?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.